ACORN CRO

ACORN CRO is committed to providing value-driven, quality deliverables to the pharmaceutical and biotechnology industry. Having sole focus and deep experience in oncology, ACORN staff fully understands how to navigate the complex clinical and operational issues..
read more...

New Therapeutics

Our New Therapeutics program, led by Dr. Daruka Mahadevan, is committed to support and accelerate your early drug development program. We understand that drug development timelines and new patient therapies must be integrated with an experienced Phase I team for successful outcomes...
read more...

HOPE

ACORN’s HOPE business line, created in 2005, conducts several types of studies involving health outcomes and economic endpoints, including prospective observational research, cross-sectional survey studies, and retrospective studies utilizing data aggregated into the ACORN Data Warehouse...
read more...